[go: up one dir, main page]

KR930012772A - 9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물 - Google Patents

9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물 Download PDF

Info

Publication number
KR930012772A
KR930012772A KR1019920022371A KR920022371A KR930012772A KR 930012772 A KR930012772 A KR 930012772A KR 1019920022371 A KR1019920022371 A KR 1019920022371A KR 920022371 A KR920022371 A KR 920022371A KR 930012772 A KR930012772 A KR 930012772A
Authority
KR
South Korea
Prior art keywords
formula
fumarate
base
alkylene
nonane
Prior art date
Application number
KR1019920022371A
Other languages
English (en)
Other versions
KR100252389B1 (ko
Inventor
붸 쉔 독토르.
발터 하이트만 독토르.
붸 맫첼 독토르.
Original Assignee
독토르. 슈바르트랜더, 독토르. 라우어
칼리-케미 파마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 독토르. 슈바르트랜더, 독토르. 라우어, 칼리-케미 파마 게엠베하 filed Critical 독토르. 슈바르트랜더, 독토르. 라우어
Publication of KR930012772A publication Critical patent/KR930012772A/ko
Application granted granted Critical
Publication of KR100252389B1 publication Critical patent/KR100252389B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

본 발명은 N,N'-디-저급알킬-치환된9,9-알킬렌-3,7-다이아자바이싸이클로 [3,1]노난화합물의 1,5-푸마르산 염에 관한 것이다. 이 염은 화학양론적으로 순수한 형태로 얻어지며 실질적으로 비흡수성이다.

Description

9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음 구조식(I)의 염기 1몰당 푸마르산 1.5몰이 함유된 구조식(I)로 표시되는 9,9-알킬렌-3,7-다이아자바이싸이를로[3,3,1]노난 화합물의 푸마르산염.
    상기 식에서, A는 탄소원자수 4-5개의 알킬렌 직쇄를 나타내고, R1과 R2는 각각 서로 다른 탄소원자수 3-4개인 직쇄 혹은 측쇄의 알킬기 또는 싸이클로프로필 메틸기를 의미한다.
  2. 제 1항에 있어서, 구조식(I)의 염기는 N, N'-다이싸이클로프로필메 틸-9,9-테트라메 틸렌-3,7-다이아자바이싸이클로[3,3,1]노난 또는 N-아이소부틸-N'-아이소프로필-9,9-펜타메 틸렌-3,7-다이아자바이싸이클로[3,3,1]노난인 것을 특징으로 하는 푸마르산염.
  3. 제2항에 있어서, 구조식(I)로 표시되는 화합물의 푸마르사나염은 N, N'-다이싸이클로프로필메틸-9,9-테트라메틸렌-3,7-다이아자바이싸이플로[3,3,1]노난-1,5-하이드로겐푸마레이트인 것을 특징으로 하는 푸마르산염.
  4. 제2항에 있어서, 구조식(I)로 표시되는 화합물의 푸마르산염은 N-아이소부-N'-아이소프로필 -9,9-펜타메틸렌-3,7-다이아자바이싸이클로[3,3,1]노난-1,5-하이드로겐푸마레이트인 것을 특징으로 하는 푸마르산염.
  5. 약리학적으로 유효량의 제1항에 따른 푸마르산염과 기타의 제약학직조재 및/또는 부헝재가 함유된 약물.
  6. 다음 구조식(I)의 염기와 저급알코올내의 적어도 1.5배 몰의 푸마르산 용액을 이보다 극성이 적은 유기용매 내에서 혼합시켜서, 구조식(I)로 표시되는 염기 1몰당 1.5몰의 푸마르산이 함유된 염을 결정 화하고, 이와같이 결정화된 염을 분리시키는 것을 특징으로 하는 구조식 (I)의 염기 1몰당 1.5몰의 푸마르산이 함유된 구조식(I)로 표시되는 9,9-알킬렌-3,7-다이아자바이싸이클로[3,3,1]노난 화합물의 푸마르산염을 제조하는 방법.
    상기 식에서, A는 탄소원자수 4-5개의 알킬렌 직쇄를 나타내고, R1과 R2는 각각 서로 다른 탄소원자수 3-4 개인 직쇄 혹은 측쇄의 알킬기 또는 싸이클로프로핀 메틸기를 나타낸다.
  7. 제6항에 있어서, 비교적 극성이 낮은 용매는 아세톤 또는 디에틸에테르인 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920022371A 1991-12-03 1992-11-25 9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물 Expired - Lifetime KR100252389B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4139763.0 1991-12-03
DE4139763A DE4139763A1 (de) 1991-12-03 1991-12-03 Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
KR930012772A true KR930012772A (ko) 1993-07-21
KR100252389B1 KR100252389B1 (ko) 2000-05-01

Family

ID=6446125

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920022371A Expired - Lifetime KR100252389B1 (ko) 1991-12-03 1992-11-25 9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물

Country Status (25)

Country Link
US (1) US5324732A (ko)
EP (1) EP0550383B1 (ko)
JP (1) JP3180848B2 (ko)
KR (1) KR100252389B1 (ko)
CN (1) CN1040758C (ko)
AT (1) ATE124411T1 (ko)
AU (1) AU652869B2 (ko)
CA (1) CA2084489C (ko)
CZ (1) CZ281930B6 (ko)
DE (2) DE4139763A1 (ko)
DK (1) DK0550383T3 (ko)
DZ (1) DZ1636A1 (ko)
ES (1) ES2073900T3 (ko)
FI (1) FI100053B (ko)
HK (1) HK1006568A1 (ko)
HU (3) HU9203698D0 (ko)
IL (1) IL103819A (ko)
LT (1) LTIP230A (ko)
MX (1) MX9206988A (ko)
NO (1) NO300687B1 (ko)
NZ (1) NZ245227A (ko)
PH (1) PH31114A (ko)
SK (1) SK332292A3 (ko)
TW (1) TW274084B (ko)
ZA (1) ZA928863B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4421324A1 (de) * 1994-06-17 1995-12-21 Kali Chemie Pharma Gmbh Neue 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen enthaltende Arzneimittel
AU2002223572B2 (en) * 2000-09-29 2005-09-08 Abbvie B.V. Ion-strength independent sustained release pharmaceutical formulation
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
WO2005011690A1 (en) * 2003-07-21 2005-02-10 Solvay Pharmaceuticals Gmbh Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
WO2005030207A1 (en) * 2003-09-26 2005-04-07 Solvay Pharmaceuticals Gmbh Use of 3, 7-diazabicyclo (3.3.1) nonane compounds for the treatment of brugada syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2551283C3 (de) * 1975-11-14 1981-02-19 Hokuriku Pharmaceutical Co., Ltd., Katsuyama, Fukui (Japan) Monofumarsäuresalz von 3-Pyridylmethylnikotinat und Verfahren zu seiner Herstellung
DE2658558A1 (de) * 1976-12-23 1978-06-29 Bayer Ag Diazabicyclo(3,3,1)nonane, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3234697A1 (de) * 1982-09-18 1984-03-22 Kali-Chemie Pharma Gmbh, 3000 Hannover Neue diazabicyclo-(3,3,1)-nonane
PT88381B (pt) * 1987-09-09 1995-07-06 Kali Chemie Pharma Gmbh Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
CA2084489A1 (en) 1993-06-04
HU210215A9 (en) 1995-02-28
NO300687B1 (no) 1997-07-07
SK279519B6 (sk) 1998-12-02
KR100252389B1 (ko) 2000-05-01
HU9203698D0 (en) 1993-03-29
LTIP230A (en) 1994-05-15
NO924647D0 (no) 1992-12-02
PH31114A (en) 1998-02-23
AU2981592A (en) 1993-06-10
SK332292A3 (en) 1998-12-02
IL103819A0 (en) 1993-04-04
ES2073900T3 (es) 1995-08-16
EP0550383A1 (de) 1993-07-07
HK1006568A1 (en) 1999-03-05
JP3180848B2 (ja) 2001-06-25
FI925482L (fi) 1993-06-04
DK0550383T3 (da) 1995-08-28
JPH05247040A (ja) 1993-09-24
DE59202726D1 (de) 1995-08-03
TW274084B (ko) 1996-04-11
ATE124411T1 (de) 1995-07-15
CZ332292A3 (en) 1993-08-11
CA2084489C (en) 2002-10-08
NO924647L (no) 1993-06-04
EP0550383B1 (de) 1995-06-28
CN1040758C (zh) 1998-11-18
HUT63417A (en) 1993-08-30
FI100053B (fi) 1997-09-15
AU652869B2 (en) 1994-09-08
CN1072931A (zh) 1993-06-09
NZ245227A (en) 1994-06-27
FI925482A0 (fi) 1992-12-02
HU213672B (en) 1997-09-29
CZ281930B6 (cs) 1997-04-16
MX9206988A (es) 1993-06-01
DE4139763A1 (de) 1993-06-09
IL103819A (en) 1996-09-12
DZ1636A1 (fr) 2002-02-17
US5324732A (en) 1994-06-28
ZA928863B (en) 1993-05-13

Similar Documents

Publication Publication Date Title
KR940011475A (ko) 신규한 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의 그의 용도
ATE14423T1 (de) Hydroxamsaeurederivate vom typ der mannich-basen mit verbesserter biologischer verfuegbarkeit von nicht-steroiden entzuendungshemmern, verfahren zur herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzung.
KR840008325A (ko) 치환된 옥타하이드로 벤조(f)퀴놀린의 제조방법
EA200000792A3 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
ZA904495B (en) Peptide derivatives,process for preparing them and pharmaceutical compositions containing them
KR930012772A (ko) 9,9-알킬렌-3,7-다이아자바이싸이클로노난 화합물의 결정성 푸마르산염과 이 화합물이 함유된 약물
RU2001102262A (ru) Нитроэфиры и нитратные соли специфических лекарственных средств
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
KR910006309A (ko) 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제
KR880009010A (ko) 신규한 테트라히드로 푸란의 5-옥시 유도체의 제조방법
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
EA200000374A3 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
ES547604A0 (es) Un procedimiento para preparar derivados de 2-piridin-tiol
KR900014305A (ko) 소염제로서의 나프탈렌메탄아미노 유도체의 용도 및 이를 함유한 약학 조성물
ES547962A0 (es) Procedimiento para la fabricacion de derivados de tiadiazol activos sobre el sistema nervioso central
KR880001561A (ko) 유효한 치료성을 갖는 신규 8-(저급알킬)비시클로[4.2.0] 옥탄 유도체
EA200100343A2 (ru) Новые гетероциклоалкилбензоциклобутановые и гетероарилбензоциклобутановые производные, способ их получения и содержащие их фармацевтические композиции
NO146744B (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme (omega-aminoalkoksy)-dibenzyl derivater
KR910007939A (ko) 헤테로사이클릭 화합물 및 이의 제조방법
FI63399C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 2'-hydroxi-2-(5-isoxazolylmetyl)-6,7-bensomorfaner och derassyraadditionssalter
SU757521A1 (ru) ΐ-АДАМАНТИЛАММОНЙЙ (э -ХЛОРЭТИЛОКСАМИНАТ, ПРОЯВЛЯЮЩИЙ АНТИСЁРОТОНИНОВУЮ АКТИВНОСТЬ
KR900018063A (ko) 하이드라지노카보닐옥시랍단, 이의 제조방법 및 약제로서의 이의 용도
KR880006251A (ko) 개선된 약물 동태학적 성질을 갖는 신규의 세팔로스포린 유도체류, 그의 제조방법 및 그를 함유한 약학 조성물
SU694497A1 (ru) 1-Адамантиламмоний -хлорэтилоксоминат, про вл ющий адреноблокирующую активность

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19921125

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970912

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19921125

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990719

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19991027

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20000118

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20000118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20030107

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20040116

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20050114

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20060116

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20070115

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20080115

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20090115

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20100115

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20110111

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20111228

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20111228

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20130809

Termination category: Expiration of duration